Business
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
Preclinical data on TARPγ8 targeted compound, an analog to Rapport’s lead product candidate RAP-219, demonstrated analgesic activity in multiple pain models
About this update from Rapport Therapeutics, Inc.
[{"type":"text","content":"Preclinical data on TARPγ8 targeted compound, an analog to Rapport’s lead product candidate RAP-219, demonstrated analgesic activity in multiple pain models\nBOSTON and SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced that the Company will present preclinical data on RTX-1738, an analog to Rapport’s lead product candidate RAP-219, across a variety of acute and chronic pain models at the upcoming International Association for the Study of Pain (IASP) 2024 World Congress on Pain taking place August 5-9, 2024, in Amsterdam, Netherlands. RTX-1738 demonstrated analgesic activity across a broad range of preclinical pain models. Details of the poster presentation are as follows: Poster Title: RTX-1738 Exhibits Analgesic Activity Across a Broad Range of Preclinical Pain Models (#TU377)Date: Tuesday, Aug. 06, 2024, 3:15 - 4:45 p.m. CESTPresenter: Jose Matta, Ph.D., Senior Director of Biology Discovery, Rapport Therapeutics For more information on IASP, please visit the event website. Following the conference, Rapport’s presentation will be available within the Publications section of the company’s website. Similar to Rapport’s lead product candidate RAP-219, RTX-1738 is an AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) negative allosteric modulator (“NAM”) designed to achieve neuroanatomical specificity through its selective targeting of a receptor associated protein (RAP) known as TARPγ8, which is associated with the neuronal AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor). RTX-1738 was used in established preclinical pain models to explore the potential of the mechanism to treat chronic pain, including peripheral neuropathic pain. RAP-219 is being studied in a Phase 2a trial in patients with drug-resistant focal epilepsy. Rapport intends to initiate Phase 2a trials evaluating RAP-219 in patients with peripheral neuropathic pain and bipolar disorder in the second half of 2024 and in 2025, respectively. About Rapport TherapeuticsRapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformational precision neu...